Gold Member Since 2016
Bettli Industry Limited

Lorcaserin Hydrochloride, Lorcaserin, Cutting Cycle Lorcaserin manufacturer / supplier in China, offering Cutting Cycle Lorcaserin Hydrochloride for Weight Lose, Superdrol Powder CAS 3381-88-2 for Muscle Building, 633-35-2 Potent Prohormones Steroids Irreversible Aromatase Inhibitor 1, 4, 6-Andorstatriene-3, 17-Dione Atd and so on.

(/ )

Supplier Homepage Product Weight Loss Drugs Cutting Cycle Lorcaserin Hydrochloride for Weight Lose

Cutting Cycle Lorcaserin Hydrochloride for Weight Lose

FOB Price: US $1-8 / grams
Min. Order: 10 grams
Min. Order FOB Price
10 grams US $1-8/ grams
Get Latest Price
Port: Hong Kong, Hong Kong
Production Capacity: 500kg/Month
Payment Terms: T/T, Western Union, Paypal, Money Gram
Basic Info
  • Model NO.: 99
  • Customized: Customized
  • Suitable for: Adult
  • Purity: >99%
  • CAS No: 846589-98-8
  • M.W: 232.1525
  • Appearance: White or Kind of White Powder.
  • Transport Package: Very Discreet or as Required
  • Origin: China
  • Powder: Yes
  • Certification: GMP, ISO 9001, USP, BP
  • State: Solid
  • Product Name: Lorcaserin Hydrochloride
  • M.F: C11h14cln@Clh
  • Assays: 99%
  • Trademark: BETTLI
  • Specification: GMP, SGS, ISO, KOSHER
  • HS Code: 3001200020
Product Description
Cutting Cycle Lorcaserin Hydrochloride for Weight Lose
Lorcaserin is a serotonergic drug. The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs]), dextromethorphan, lithium, antipsychotics or other dopamine antagonists, particularly when used in combination [see Drug Interactions].
 
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form, can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.
 
The safety of lorcaserin when coadministered with other serotonergic or antidopaminergic agents, including antipsychotics, or drugs that impair metabolism of serotonin, including MAOIs, has not been systematically evaluated and has not been established.
 
If concomitant administration of lorcaserin with an agent that affects the serotonergic neurotransmitter system is clinically warranted, extreme caution and careful observation of the patient is advised, particularly during treatment initiation and dose increases. Treatment with lorcaserin and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated [see Adverse Reactions and Drug Interactions
 
Regurgitant cardiac valvular disease, primarily affecting the mitral and/or aortic valves, has been reported in patients who took serotonergic drugs with 5-HT2B receptor agonist activity. The etiology of the regurgitant valvular disease is thought to be activation of 5-HT2B receptors on cardiac interstitial cells. At therapeutic concentrations, lorcaserin is selective for 5-HT2C receptors as compared to 5-HT2B receptors. In clinical trials of 1-year duration, 2.4% of patients receiving lorcaserin and 2.0% of patients receiving placebo developed echocardiographic criteria for valvular regurgitation at one year (mild or greater aortic regurgitation and/or moderate or greater mitral regurgitation): none of these patients was symptomatic [see Adverse Reactions].
 
Lorcaserin has not been studied in patients with congestive heart failure or hemodynamically-significant valvular heart disease. Preliminary data suggest that 5HT2B receptors may be overexpressed in congestive heart failure, Therefore, lorcaserin should be used with caution in patients with congestive heart failure.
 
Lorcaserin should not be used in combination with serotonergic and dopaminergic drugs that are potent 5-HT2B receptor agonists and are known to increase the risk for cardiac valvulopathy (e.g., cabergoline).
 
Patients who develop signs or symptoms of valvular heart disease, including dyspnea, dependent edema, congestive heart failure, or a new cardiac murmur while being treated with lorcaserin should be evaluated and discontinuation of lorcaserin should be considered.

Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus treated with insulin and/or insulin secretagogues (e.g., sulfonylureas); hypoglycemia was observed in clinical trials with lorcaserin. Lorcaserin has not been studied in combination with insulin. Measurement of blood glucose levels prior to starting lorcaserin and during lorcaserin treatment is recommended in patients with type 2 diabetes. Decreases in medication doses for anti-diabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. If a patient develops hypoglycemia after starting lorcaserin, appropriate changes should be made to the anti-diabetic drug regimen [see Adverse Reactions].

Lorcaserin moderately elevates prolactin levels. In a subset of placebo-controlled clinical trials of at least one year in duration, elevations of prolactin greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal, measured both before and 2 hours after dosing, occurred in 6.7%, 1.7%, and 0.1% of lorcaserin-treated patients and 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively [see Adverse Reactions]. Prolactin should be measured when symptoms and signs of prolactin excess are suspected (e.g., galactorrhea, gynecomastia). There was one patient treated with lorcaserin who developed a prolactinoma during the trial. The relationship of lorcaserin to the prolactinoma in this patient is unknown.

 
Clinical Trials Experience
 
In the lorcaserin placebo-controlled clinical database of trials of at least one year in duration, of 6888 patients (3451 lorcaserin vs. 3437 placebo; age range 18-66 years, 79.3% women, 66.6% Caucasians, 19.2% Blacks, 11.8% Hispanics, 2.4% other, 7.4% type 2 diabetics), a total of 1969 patients were exposed to lorcaserin 10 mg twice daily for 1 year and 426 patients were exposed for 2 years.
 
In clinical trials of at least one year in duration, 8.6% of patients treated with lorcaserin prematurely discontinued treatment due to adverse reactions, compared with 6.7% of placebo-treated patients. The most common adverse reactions leading to discontinuation more often among lorcaserin treated patients than placebo were headache (1.3% vs. 0.8%), depression (0.9% vs. 0.5%) and dizziness (0.7% vs. 0.2%).
NameCAS NOStandard/Purty
Boldenoe propionateN/A98%
Boldenoe undecylenate/EQ13103-34-997%
Boldenone cypionate 99%
Boldenoen acetate 99%
Chlordehydromethyl Testostero Acetate/clostebol acetate855-19-699%
Oxymethol434-07-1USP
Oxandrol53-39-4USP
Drostanolone Propionate521-12-098%
Drostanolone enanthate472-61-14598%
Exemest/Aromasin107868-30-498%
SustanonN/A98%
Stanozl/Winstrol10418-03-8USP
Testos/Testo Suspension58-22-0USP
Testo Cypionate58-20-8USP
Testo Decanoate5721-91-5USP
Testo Enanthat315-37-7USP
Testo Isocaproate15262-86-9USP
Testo Phyenylpropionate1255-49-8USP
Testo Propionate57-85-2USP
Testo Undecanoate5949-44-0CP2005
Testo acetate1045-69-898%
Trenb Acetate10161-34-9USP
Trenb EnanthateN/AUSP
Trenb Hexa23454-33-398%
Mestanol521-11-998%
Mesterol/proviron1424-00-6BP
Methandnone/Dianabol72-63-9BP
Methenol Acetate /Primobolan434-05-998%
Methenol Enanthate303-42-498%
Methyltesto58-18-4USP
Nandrol Decanoate360-70-3USP
Nandrol Phenypropionate62-90-8USP
 4-chloro-17a-methyl androst-1,4 diene-3-17b-dione/turinabol  2446-23-398%
17a-Methyl-1-Testo58-18-498%

Cutting Cycle Lorcaserin Hydrochloride for Weight Lose
 
SUPERIORITY 
1. Satisfied prices with fine quality; 
2. The package's Courier (EMS, DHL, FedEx, UPS) is choosed by the clients. 
3. The right to choose the packing way for his products from many recent effective packing ways belongs to the clients; 
4. Specials are possible when client's order is big enough, including the discount policy; 
5. Our company promises to deliver the package to the clients safely, or we'll cover the total loss and reship in time;  
Send your message to this supplier
Avatar
Mr. Jason
Sales Manager
*From:
To: Mr. Jason
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category